OnKure Therapeutics (OKUR) Operating Expenses (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Operating Expenses came in at $15.6 million in Q1 2026, down 8.15% YoY from $17.0 million in Q1 2025, and up 10.55% on a QoQ basis from $14.1 million in Q4 2025.
OnKure Therapeutics (OKUR) Operating Expenses (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Operating Expenses data on file, last reported at $15.6 million in Q1 2026.
- Quarterly Operating Expenses fell 8.15% year-over-year to $15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.6 million (changed 0.02% YoY) and the FY2025 annual result came in at $63.0 million, up 15.75% from the prior year.
- Operating Expenses climbed to $15.6 million in Q1 2026, from $14.1 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $21.0 million in Q2 2023 to a low of -$21.1 million in Q4 2023.
- A 5-year average of $13.2 million and a median of $14.6 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses sank 244.99% — and 2024, when it soared 188.57%.
- Tracing OKUR's Operating Expenses over 5 years: stood at $14.6 million in 2022, then slumped by 244.99% to -$21.1 million in 2023, then soared by 188.57% to $18.7 million in 2024, then retreated by 24.46% to $14.1 million in 2025, then grew by 10.55% to $15.6 million in 2026.
- The last three Operating Expenses figures came in at $15.6 million (Q1 2026), $14.1 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | 16.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.90 Mn |
| Mar 31, 2026 | 15.62 Mn |
| Dec 31, 2025 | 14.13 Mn |
| Sep 30, 2025 | 15.50 Mn |
| Jun 30, 2025 | 16.32 Mn |
| Mar 31, 2025 | 17.00 Mn |
| Dec 31, 2024 | 18.70 Mn |
| Sep 30, 2024 | 11.51 Mn |
| Jun 30, 2024 | 14.34 Mn |
| Mar 31, 2024 | 9.83 Mn |
| Dec 31, 2023 | -21.11 Mn |
| Sep 30, 2023 | 20.89 Mn |
| Jun 30, 2023 | 21.04 Mn |
| Mar 31, 2023 | 16.12 Mn |
| Dec 31, 2022 | 14.56 Mn |
| Sep 30, 2022 | 13.84 Mn |
| Jun 30, 2022 | 12.43 Mn |
| Mar 31, 2022 | 13.02 Mn |
| Dec 31, 2021 | 10.62 Mn |
| Sep 30, 2021 | 12.75 Mn |